- Home
- MRNA vs BNTX Comparison
MRNA vs BNTX Comparison
Compare MRNA & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | BNTX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | Germany |
| Employees | N/A | 7807 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 24.2B |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MRNA | BNTX |
|---|---|---|
| Price | $50.96 | $95.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $34.27 | ★ $133.38 |
| AVG Volume (30 Days) | ★ 5.3M | 886.3K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $8.74 | N/A |
| Revenue Next Year | $16.18 | $4.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $79.81 |
| 52 Week High | $59.55 | $124.00 |
Technical Indicators
Market Signals| Indicator | MRNA | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 54.91 |
| Support Level | $47.61 | $95.13 |
| Resistance Level | $54.94 | $114.06 |
| Average True Range (ATR) | 2.53 | 2.44 |
| MACD | -0.21 | 1.34 |
| Stochastic Oscillator | 50.66 | 96.70 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.